Iron overload diseases encompass a large spectrum of genetic and acquired disorders. The symptoms induced by chronic iron excess are close, whatever the etiology, and may cause significant morbidity and mortality representing a worldwide health problem. The diagnosis of iron overload is now based on a non invasive approach, resting on clinical, biological and imaging data. The treatment, which depends on the mechanisms underlying the development of iron overload, is mainly based on venesection or chelation therapy. However, in light of major advances in the pathophysiological understanding of these diseases(1), a number of promising innovative therapeutic approaches are emerging. Fig.1) 1.1. CAUSES
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GENETIC IRON OVERLOAD DISORDERS
They correspond to various forms of hemochromatosis (HC)(2, 3).
1.1.1.1. HFE-related hemochromatosis. Also called Type 1-HC, it is by far the most frequent form of genetic iron overload disease. The usual underlying genotype is homozygosity for the C282Y mutation(4) (new HFE terminology p.Cys282Tyr). Type 1 HC is exclusively present in the caucasian (white) population, with a prevalence of homozygosity close to 3 per thousand.
C282Y homozygosity should be considered as a mere predisposition for the disease since phenotypic expression is quite variable (due to incomplete penetrance of the gene). It has thus been reported that approximately only 1% of homozygote women and less than 30% of homozygote men may develop a fully expressed form of the disease (5) , compromising both quality of life and life expectancy. Type 1 HC is an adult disease, most often expressed after 30 and 40 years old in men and women, respectively. It should also be noted that some data have pointed out the possible physical advantage provided by HFE mutations (6, 7).
1.1.1.2. Non HFE-related HC. They are rare diseases, but present in both caucasian and non-caucasian populations (8, 9) . i) Type2 HC corresponds to a severe form of iron overload occurring in younger individuals (less than 30 years old), and therefore called juvenile HC. It is due to mutations of the hemojuvelin (HFE2 or HJV) gene or of the HAMP (hepcidin) gene (corresponding to types 2A and 2B HC, respectively). ; ii) Type3 HC is due to mutations of the transferrin receptor 2 (TFR2) gene. Usually expressed in adults, it may also cause juvenile HC ; iii) Type4 HC. Due to mutations of the ferroportin (SLC40A1) gene, it is the only form of HC with a dominant mode of transmission. In its usual form (called type A), the mutations alter the export function of ferroportin. In the type B form, the mutations alter the hepcidin receptor function of ferroportin, leading to a refractoriness state toward hepcidin ; iv) Hereditary aceruloplasminemia (HA) (see below) may also be classified among non-HFE related HC.
1.1.1.3. Compared prevalences of HFE and non-HFE HC. Types 1, 2 and 3 HC are very rare as compared to HFE-HC. It has been reported that the predictive frequency of HFE pathogenic genotypes was approximately 1/1000, versus 1/5000 000 for type 2A HC, 1/6000 000 for type 3 HC, and 1/180 000 000 for type 2B HC. Unexpectedly, the frequency for type 4 HC was close to that of type1 HC (1/1300), partly due to the dominant nature of the disease(9). -Hepcidin deficiency is the prevailing mechanism in types 1, 2 and 3 HC as well as in dyserythropoiesis. The common mechanistic denominator is the decreased hepatic production of hepcidin which is the master regulator of systemic iron (14) (15) (16) . This decrease is due, in HC, to the involved mutations and, in dyserythropoiesis, to the action of the bone marrow hormone erythroferrone (ERFE) (17, 18) . The subsequent decreased plasma hepcidin concentration induces both an increased duodenal iron absorption, and an increased release by the spleen of the iron coming from the normal degradation of senescent erythrocytes (erythrophagocytosis). The consequence is a chronic elevation of plasma iron concentration. Part of this iron is, as physiologically expected, taken up by its plasma carrier protein, transferrin, forming transferrin-iron.
Transferrin-iron is essentially delivered to the bone marrow in order to contribute to the production of new red blood cells. But, due to the high levels of plasma iron, the quantity of circulating transferrin is insufficient to bind all of the metal, so that iron becomes partially present under another form, called non-transferrin bound iron (NTBI) (19, 20) . NTBI, which is likely bound to low molecular weight ligands such as citrate and acetate but also to albumin, has the very special kinetic property to be very avidly taken up, not by the bone marrow, but by various parenchymal cells, especially in the liver (hepatocytes), pancreas, and heart. Therefore, NTBI is considered as the main responsible for iron excess development in many organs.
-Hepcidin refractoriness (type4B-HC). Although plasma hepcidin concentration is not decreased, the down-stream cellular consequences are similar to those occurring in quantitative hepcidin deficiency.
-Iatrogenic excessive body iron intake : It corresponds to excessive parenteral administration of iron, either as iron per se (intravenous infusions) or through multiple transfusions, the erythrocytes being very iron rich (they represent half of the total body iron content).The fate of parenteral iron is to be stored within the reticuloendothelial system (macrophages), namely essentially in the spleen. This storage process is very fast for infused iron and postponed to the end of erythrocyte life for transfusional iron. Iron is subsequently released into the blood stream, leading to increased transferrin saturation and to NTBI production. Iron is known for its involvement in the Fenton reaction leading to ROS production (23) . The iron species involved in this toxic reaction is not transferrin-iron, but a special NTBI component, named labile plasma iron (LPI) (24) (25) (26) (27) . This iron species is able to target cellular membranes and nuclei, and is considered the main culprit for iron-related cellular and organ damage. -Iron toxicity depends on the cellular type affected by iron deposition.
Thus, iron is more damaging to parenchymal cells (typically the hepatocytes), than to reticuloendothelial cells (typically the macrophages).
-The liver is a critical cross road in the process of body iron toxicity :i) as a major iron storage organ, it is capable, for a long period, to protect many other organs from becoming iron overloaded ; ii) however, when this role of reservoir is overwhelmed by the duration and intensity of iron overload, the liver may loose its « bulwark » property, opening the road for extra-hepatic iron toxicity ; iii) in chronic liver failure -whatever its etiology-the decreased production by the hepatocytes of transferrin and hepcidin(28) may favor body iron overload and toxicity. Indeed, both mechanisms contribute to increase plasma transferrin saturation (through decreased plasma transferrin concentration and increased iron concentration, respectively), leading to the formation of plasma NTBI and LPI ; iv) the liver is a preferential target of iron toxicity. Being a storage organ is in fact a double-edged sword with the risk of progressive iron-related hepatocyte damage, leading to fibrosis, cirrhosis, and even hepatocellular carcinoma.
-The role of cofactors acting as modulators of iron overload and toxicity is increasingly acknowledged. These factors can be environmental (acquired), such as menstruations or pregnancies which can contribute to decrease iron overload, or chronic alcoholism which may aggravate hepatic iron toxicity (29) . The cofactors can also be genetic. In HFE-HC, the presence of a mutation in the hepcidin promoter is associated with massive iron overload (30) . Moreover, in this disease, GNAP(31), TMPRSS6 (32) , and PCSK7(33) polymorphisms have been reported to aggravate iron overload, to decrease iron overload, and to accentuate hepatic fibrosis , respectively. Fig.2) 
DIAGNOSTIC ASPECTS (
GLOBAL DIAGNOSTIC STRATEGY
It is a multi-step process.
CLINICAL APPROACH
It is the prerequisite of any diagnostic search, and should explore systematically general health and the various organs, since chronic iron overload corresponds to a systemic disease. Thus, the main syndromes, more ou less associated, are :
chronic fatigue, joint pains, bone demineralization, melanodermia (increased skin pigmentation), liver signs (hepatomegaly, moderate transaminase increase), diabetes, or cardiac symptoms (rhythm disturbances, cardiac failure). is essential to interpret rigorously hyperferritinemia since it can be related to a number of causes without significant body iron excess(34). Among those situations : i) inflammation since ferritin is an acute-phase reactant protein.
The macrophagic activation syndrome(35) is very close to this mechanism.
Occurring in some infectious, hematological or auto-immune diseases it can be expressed by dramatic levels of hyperferritinemia ; ii) cytolysis, especially during acute or chronic hepatitis ; iii) alcoholism ; iv) metabolic hyperferritinemia which is likely to represent the most frequent cause of hyperferritinemia (36) . Usually associated to plasma levels below 1000 µg/L, metabolic hyperferritinemia is diagnosed on a number of convergent increase plasma iron(hemolysis, cytolysis), or decrease it (inflammation).
-Plasma transferrin saturation (TS). It corresponds to the ratio of iron on transferrin, and is normally less than 45%. This parameter is still too often ignored, whereas its determination (which should, at best, be based on two successive controls) provides, in iron overloaded ii) quantifying iron overload (histological semi-quantification and/or biochemical determination fo liver iron concentration) ; iii) orientating the etiology (hepatocyte versus macrophage iron deposition) ; iv) assessing liver fibrosis, and iv) searching for cofactors of hepatic toxicity, such as features of metabolic syndrome or alcoholism.
2.2.OPTIMISING THE DIAGNOSTIC STRATEGY
DIAGNOSING IRON OVERLOAD HAS BECOME A NON INVASIVE APPROACH
Whereas, for a long time, performing a liver biopsy was an indispensable step, it is no more so for the following reasons :
-Proving, quantifying, and assessing indirectly cellular distribution (via the balance between liver and spleen iron deposition) can be accurately achieved by MRI.
-Transient elastography is increasingly performed, as a non invasive surrogate for liver biopsy, to assess liver fibrosis(47).
NEW PROMISING BIOLOGICAL TOOLS ARE EMERGING
-A number of recent biochemical parameters should, in the near future, be more and more applied to investigate disorders of iron metabolism. Among them, the measurements of plasma NTBI, LPI, and possibly hepcidin concentrations.
-The recent advances in molecular biology, especially through next generation sequencing (NGS), are already transforming the genetic diagnosis for ironrelated disorders (48) . This high throughput approach is a powerful way to identify mutations. However, it raises interpretation issues since it is able to identify a number of new variants of which it is difficult to know whether or not they are harmful.
CLINICAL UTILITY TO PROPOSE THE CONCEPT OF HEPCIDIN-DEPRIVATION SYNDROME (HDS)
The HDS syndrome, observed in all cases of HC (but type A ferroportin disease) and in dyserythropoiesis, can be characterized by the association of increased plasma transferrin saturation, parenchymal (hepatocyte) iron deposition, and absence of splenic iron overload. It exposes to severe complications of iron overload, due to the parenchymal LPI impact.
SETTING UP NATIONAL AND INTERNATIONAL REFERENCE CENTERS AND
NETWORKS, for improving the diagnosis of iron overload disorders related to rare HFE or non-HFE mutations, should be part of the health decision-maker policies.
3.THERAPEUTIC ASPECTS (Fig.3) blood pressure) and on hemoglobin (Hb) levels which should not decrease below 11g/dL or by more than 2g compare to baseline levels.
3.1.CURRENTLY AVAILABLE THERAPEUTIC TOOLS AND STRATEGIES
Efficacy follow-up. It is based on plasma ferritin levels, checked every month
until the values reach the upper normal limits, and every two weeks thereafter, until the final goal of ferritinemia levels close to 50 µg/L is reached. It should be kept in mind that transferrin saturation levels remain high until the very end of the induction phase, so that this parameter is not appropriate for evaluating the gradual decrease of iron excess due to the venesections. After iron depletion has been achieved, the maintenance phase starts, lasting, theoretically, for the whole life, and aiming to maintain ferritin levels close to 50 µg/L. It usually consists of one venesection every 2 to 4 months.
3.1.1.6. Results. In HC due to hepcidin deficiency, venesection therapy is globally well tolerated although, in a recent international survey on 210 type HC patients(51), 52% of induction patients and 37% of maintenance patients experienced side effects "always"
or "most of the time" after phlebotomy. The overall efficacy to remove iron overload is excellent and many symptoms improve ; however, the joint symptoms may not been improved and even deteriorate or appear under depleting treatment (52, 53 3.1.2.5. Efficacy. All three compounds are efficient. DFP has an interesting efficacy on cardiac iron overload (55) . DFX is able to negativate iron balance and to exert beneficial hepatic effects on iron-related hepatic inflammation and fibrosis(56).
FAMILY SCREENING (GENETIC DISEASES)
3.1.3.1. General strategy. Family screening is based on the following three main data :
i) the genetic profile that has been identified in the proband and serves as a marker to evaluate genetic predisposition among the relatives, ii) the phenotypic markers, combining plasma transferrin saturation and ferritin levels, and iii) the recessive or dominant mode of transmission of the disease.
Differential strategies :
-Quantitative hepcidin deficiency-related HC (types1, 2, or 3 HC). i) Type1
(C282Y/C282Y)-HC (44) . Only C282Y homozygosity exposes to the disease risk, keeping however in mind that homozygosity does not mean « disease » (due the partial penetrance of the gene).
Siblings (genetically explored only after the age of 18) are the primary at risk relatives.
However, given the high HFE mutation prevalence, it is recommended to screen genetically also the offspring (after age 18). For the parents, it is usually sufficient to check the phenotypic markers, limiting the genetic study to the cases with phenotypic suggestion of established iron excess. ii) Type2 -HC. Being exceptional, recessive, and juvenile diseases, screening should focus on the siblings (whatever their age). iii) Type3-HC. The screening strategy is close to that of Type1-HC with the differences that, being a rare disease, the offspring are not at risk, and that, since young individuals may be affected, siblings should be explored whatever their age. Developing family screening centers which are necessary when considering the frequent geographical scatttering of the relatives ; iii) Setting up national and international reference centers in the field of genetic iron overload disorders ; iv) As to the mass screening of caucasian populations, it remains debated but seems a reasonable preventive goal in view of the following data : HFE-HC is a frequent disease, with a long clinically asymptomatic phase, an easy and non invasive diagnosis, and furthermore an effective treatment.
-From the medical and scientific viewpoint, preventive improvements should come from two main directions : one is to identify predictive markers of phenotypic expression, another one is to investigate the interest of hepcidin supplementation, especially for preventing iron overload development in early diagnosed (and potentially expressing)
homozygotes, and to avoid iron overload reconstitution after the end of the induction phase.
ACQUIRED DISEASES (TRANSFUSIONAL IRON OVERLOAD)
Associating plasma iron, transferrin saturation and ferritin determination together with MRI assessment of iron overload, should permit to start the chelation therapy as early as possible.
In conclusion, the iron overload field concerns a wide variety of potentially severe diseases of genetic or acquired origin. Key advances in the knowledge of iron metabolism joined to major biological, pharmacological and technological improvements have considerably improved the diagnostic and therapeutic approaches of these diseases. The active ongoing research in these domains is opening highly promising roads for continuous amelioration of patient care.
EXPERT COMMENTARY
In contrast to iron deficiency which is widely recognized as a major health problem, iron overload disorders remain poorly known to the general population and even to the medical community, probably largely due to the fact that iron remains, in our collective unconscious, synonymous with strentgh and good health. It is therefore important to disseminate informations concerning the major recent advances in the diagnostic and therapeutic management of these iron overload disorders which, whatever their genetic or acquired origin, may severely impact the quality of life and life expectancy of the affected adults or children.
FIVE-YEAR VIEW
-For genetic iron overload, especially related to hepcidin deficiency, many new variants will be discovered and it is hoped that some of them will permit to predict the phenotypic expression of the genetic predisposition. This prediction should ideally concern not only the amount of iron overload expected in the absence of treatment but the target organs likely to be affected in case of iron excess. An earlier diagnosis, thanks to increase awareness of the diseases and to extended phenotypic screening (based on plasma iron and/or transferrin saturation and/or ferritin levels), should, together with novel predictive markers of phenotypic expression, permit to initiate preventive therapy, ideally consisting of hepcidin supplementation.
-For transfusional iron overload, the diagnosis should benefit from greater accessibility to MRI permitting to start the treatment as soon as possible. One cannot exclude that novel oral iron chelators will be developed during this period but defining the best combined strategies with the existing chelators appear the most promising orientation.
Whether hepcidin supplementation will have a significant role in the therapeutic approach of this type of iron overload is a very stimulating perspective.
KEY ISSUES
• Iron is crucial for life but iron overload, like iron deficiency, can be severely deleterious for the human body.
• Iron overload can be of genetic or acquired origin. Hemochromatosis and transfusional iron overload are the respective archetypes of the corresponding diseases.
• Hemochromatosis is due to either increased iron entry in the cells or decreased cellular iron egress. Hepcidin and (usual) ferroportin deficiencies are the respective mechanisms underlying these two types of hemochromatosis.
• Iron overload due to hepcidin deficiency is characterized by high plasma iron and transferrin saturation together with parenchymal (essentially hepatocyte) iron deposition.
• Plasma NTBI (non-transferrin bound iron) and its LPI (labile plasma iron) component are new iron species, responsible for iron overload and iron toxicity, respectively.
• MRI (magnetic resonance imaging) has become the non-invasive technique of reference for assessing hepatic (and splenic) iron load.
• Next generation sequencing is transforming the genetic diagnostic strategy and should be handled by expert centers.
• Venesection therapy remains the basis for removing iron excess in diseases related to hepcidin deficiency and could be, in the future, associated with (or replaced by) hepcidin supplementation.
• Chelation therapy has greatly benefited from the introduction of oral chelators.
Combining different chelators represents a promising therapeutic perspective.
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